Abstract
Respiratory syncytial virus (RSV) is a potentially life-threatening infection in premature infants. We report an outbreak involving four infants in the neonatal intensive care unit (NICU) of our hospital that occurred in February 2010. RSV A infection was confirmed by real-time polymerase chain reaction. Palivizumab was administered to all infants in the NICU. There were no additional symptomatic cases and repeat RSV surveillance confirmed that there was no further cross-transmission within the unit. The outbreak highlighted the infection control challenge of very high bed occupancy in the unit and the usefulness of molecular methods in facilitating detection and management.
Copyright © 2011 the Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents / administration & dosage*
-
Cross Infection / drug therapy
-
Cross Infection / epidemiology*
-
Cross Infection / prevention & control
-
DNA, Viral / genetics
-
DNA, Viral / isolation & purification
-
Disease Outbreaks*
-
Female
-
Genotype
-
Humans
-
Infant
-
Infant, Newborn
-
Infection Control / methods
-
Intensive Care, Neonatal
-
Palivizumab
-
Polymerase Chain Reaction
-
Respiratory Syncytial Virus Infections / drug therapy
-
Respiratory Syncytial Virus Infections / epidemiology*
-
Respiratory Syncytial Virus Infections / prevention & control
-
Respiratory Syncytial Virus, Human / classification
-
Respiratory Syncytial Virus, Human / drug effects
-
Respiratory Syncytial Virus, Human / genetics
-
Respiratory Syncytial Virus, Human / isolation & purification*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Antiviral Agents
-
DNA, Viral
-
Palivizumab